Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| APTARGROUP, INC.ATR · Entity 165 | Director | July 16, 2026 | July 17, 2026 |
| Criteo S.A.CRTO · Entity 291 | Chief Financial Officer | August 06, 2026 | August 07, 2026 |
| XPO, Inc.XPO · Entity 3242 | Acting Chief Financial Officer | June 10, 2019 | June 11, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
APTARGROUP, INC.
Report date July 16, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,553 |
Reported balance
After 2026-07-16 transaction · row 1
1 source rowRow 1 · 2026-07-16 · Grant · Acquired 151 · Balance 4,553 |
Criteo S.A.
Report date August 06, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 424,612 |
Reported balance
After 2026-08-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-06 · Sale · Disposed 6,285 · Balance 424,612 F1: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F2: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award.
F2: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission.
XPO, Inc.
Report date June 10, 2019 · Filed June 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 1,951 |
Ending reported balance
After 2019-06-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-06-10 · Exercise / conversion · Acquired 2,842 · Balance 2,842 Row 2 · 2019-06-10 · Tax withholding · Disposed 891 · Balance 1,951 F1: No shares were sold by the Reporting Person. These shares were withheld by the Issuer to fund tax liability attributable to the vesting and settlement of the Restricted Stock Units ("RSUs") reported on this Form 4. These RSUs vested on June 8, 2019, as originally scheduled, and were settled on June 10, 2019, and there were no related discretionary transactions or open market sales. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 14,208 |
Reported balance
After 2019-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-06-10 · Exercise / conversion · Disposed 2,842 · Balance 14,208 F2: Each RSU represents a contingent right to receive, upon settlement, either (i) one share of Common Stock or (ii) a cash payment equal to the fair market value of one share of Common Stock. F3: The RSUs vest in six equal annual installments, beginning on June 8, 2019 and continuing to vest on the next five anniversaries thereof, generally subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: No shares were sold by the Reporting Person. These shares were withheld by the Issuer to fund tax liability attributable to the vesting and settlement of the Restricted Stock Units ("RSUs") reported on this Form 4. These RSUs vested on June 8, 2019, as originally scheduled, and were settled on June 10, 2019, and there were no related discretionary transactions or open market sales.
F2: Each RSU represents a contingent right to receive, upon settlement, either (i) one share of Common Stock or (ii) a cash payment equal to the fair market value of one share of Common Stock.
F3: The RSUs vest in six equal annual installments, beginning on June 8, 2019 and continuing to vest on the next five anniversaries thereof, generally subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
2seventy bio, Inc.
Report date May 13, 2025 · Filed May 15, 2025
Section 16 reporting ended · disclosed 2025-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-05-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-13 · Disposition to issuer · Disposed 12,050 · Balance 15,602 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Row 2 · 2025-05-13 · Other · Disposed 15,602 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93 | Direct | 0 |
Reported balance
After 2025-05-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-13 · Disposition to issuer · Disposed 24,100 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger").
F2: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law.
F4: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration.
bluebird bio, Inc.
Report date November 11, 2021 · Filed November 17, 2021
Section 16 reporting ended · disclosed 2021-11-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-11-11 · Other · Acquired 0 · Balance 0 F1: Represents restricted stock units awarded to the reporting person prior to the separation (the "Separation") of 2seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the Employee Matters Agreement by and between 2seventy and bluebird (the "EMA") such that the reporting person received restricted stock units of 2seventy to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on September 29, 2021 and vests vest ratably over three years in annual installments commencing on September 29, 2021. F2: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2031-09-29 | Direct | 0 |
Reported balance
After 2021-11-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-11 · Other · Disposed 7,500 · Balance 0 F4: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on September 29, 2021 and vests ratably over three years in annual installments commencing on September 29, 2021. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units awarded to the reporting person prior to the separation (the "Separation") of 2seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the Employee Matters Agreement by and between 2seventy and bluebird (the "EMA") such that the reporting person received restricted stock units of 2seventy to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on September 29, 2021 and vests vest ratably over three years in annual installments commencing on September 29, 2021.
F2: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP").
F3: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP.
F4: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on September 29, 2021 and vests ratably over three years in annual installments commencing on September 29, 2021. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2023 Filed Jan 24, 2023 21:08 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 2,827 | $28.95 | $81,835.15 |
DisclosureSEC source: 0001576427-23-000002 · wf-form4_167459447558440.xml · nonDerivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,074 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of previously-reported security awards. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission ("SEC"). Read SEC document |
| January 23, 2023 Filed Jan 24, 2023 21:08 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 2,827 | $28.95 | $81,835.15 |
DisclosureSEC source: 0001576427-23-000002 · wf-form4_167459447558440.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,901 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of previously-reported security awards. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission ("SEC"). Read SEC document |
| October 24, 2022 Filed Oct 25, 2022 20:12 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 28,224 | $26.05 | $735,136.42 |
DisclosureSEC source: 0001576427-22-000089 · wf-form4_166672872804076.xml · nonDerivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,728 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the reporting person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the issuer held by the reporting person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission ("SEC"). Read SEC document |
| October 24, 2022 Filed Oct 25, 2022 20:12 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 25,510 | $26.05 | $664,446.22 |
DisclosureSEC source: 0001576427-22-000089 · wf-form4_166672872804076.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,952 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the reporting person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the issuer held by the reporting person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission ("SEC"). Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 18:20 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (right to buy) · Derivative | 14,400 | $0.00 Strike: $13.51 | $0.00 |
DisclosureSEC source: 0001562180-22-004991 · primarydocument.xml · derivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,400 Underlying: Common Stock · 14,400 shares Expires 2032-06-08 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 8, 2023 or the date of the next annual meeting of stockholders of 2seventy bio, Inc. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 18:20 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 4,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-004991 · primarydocument.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,202 F1 · security: These restricted stock units vest 100% on the earlier of June 8, 2023 or the date of the next annual meeting of stockholder of 2seventy bio, Inc. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 23:33 UTC | Criteo S.A. CRTO · Entity 291 | GrantOrdinary Shares | 110,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001576427-22-000014 · wf-form4_164609114076941.xml · nonDerivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,462 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F4 · shares: On October 23, 2020, the reporting person was granted performance-based stock units covering 110,327 shares of the Issuer at the target performance level, which would become eligible to vest based on the achievement of performance goals. On February 24, 2022, the performance criteria were met, resulting in 110,327 shares becoming eligible to time based vesting as follows: 50% of the shares will vest on the two-year anniversary of the grant date, and the remainder will vest in equal portions at the end of each quarter during the two-year period thereafter. F3 · balance_after: For more information about the equity of the issuer held by the reporting person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission ("SEC"). Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 23:33 UTC | Criteo S.A. CRTO · Entity 291 | GrantOrdinary Shares | 36,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001576427-22-000014 · wf-form4_164609114076941.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,135 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F2 · shares: The shares are subject to time based vesting as follows: 50% of the shares will vest on the two-year anniversary of the grant date, and the remainder will vest in equal portions at the end of each quarter during the two-year period thereafter. F3 · balance_after: For more information about the equity of the issuer held by the reporting person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission ("SEC"). Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:36 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (right to buy) · Derivative | 4,829 | $0.00 Strike: $29.48 | $0.00 |
DisclosureSEC source: 0001628280-21-023466 · wf-form4_163706252004084.xml · derivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,829 Underlying: Common Stock · 4,829 shares Expires 2031-09-29 F4 · shares: This option vests ratably over three years in annual installments commencing on 09/29/2021 (see footnotes 2 and 3). F4 · derivative.exercise_date: This option vests ratably over three years in annual installments commencing on 09/29/2021 (see footnotes 2 and 3). Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:36 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 3,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023466 · wf-form4_163706252004084.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,002 F1 · security: In connection with the separation (the "Separation") of seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"), the reporting person received restricted stock units, each representing the right to receive a share of 2seventy's common stock, as a result of the adjustment of existing bluebird restricted stock units prior to the Separation (see footnotes 2 and 3). The restricted stock unit award vests ratably over three years in annual installments commencing on 09/29/2021. F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP"), the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date (the "2seventy VWAP") multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: The number of shares underlying the converted 2seventy equity awards was determined by multiplying the number of shares underlying the existing bluebird equity awards by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the sum of (1) the 2seventy VWAP multiplied by the distribution ratio and (2) the quotient obtained by dividing the bluebird Post-Distribution VWAP by the distribution ratio. bluebird equity awards granted on or after January 1, 2021, such equity awards were converted into 2seventy equity awards. The number of shares of 2seventy common stock underlying such converted equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the 2seventy VWAP. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 13:56 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023646 · wf-form4_163715736286125.xml · derivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2031-09-29 F4 · derivative.exercise_price: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on September 29, 2021 and vests ratably over three years in annual installments commencing on September 29, 2021. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F4 · shares: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on September 29, 2021 and vests ratably over three years in annual installments commencing on September 29, 2021. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F4 · derivative.exercise_date: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on September 29, 2021 and vests ratably over three years in annual installments commencing on September 29, 2021. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 13:56 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023646 · wf-form4_163715736286125.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Represents restricted stock units awarded to the reporting person prior to the separation (the "Separation") of 2seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the Employee Matters Agreement by and between 2seventy and bluebird (the "EMA") such that the reporting person received restricted stock units of 2seventy to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on September 29, 2021 and vests vest ratably over three years in annual installments commencing on September 29, 2021. F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 23:27 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $18.98 | $0.00 |
DisclosureSEC source: 0001562180-21-006221 · primarydocument.xml · derivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-09-29 F2 · derivative.exercise_date: This option vests ratably over three years in annual installments commencing on September 29, 2021. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 23:27 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 4,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-006221 · primarydocument.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,663 F1 · security: These restricted stock units for common stock vest ratably over three years in annual installments commencing on September 29, 2021. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 20:00 UTC | Criteo S.A. CRTO · Entity 291 | GrantOrdinary Shares | 110,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001576427-20-000095 · wf-form4_160382878795424.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,327 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F2 · shares: The shares are subject to time based vesting as follows: 50% of the shares will vest on the two-year anniversary of the grant date, and the remainder will vest in equal portions at the end of each quarter during the two-year period thereafter. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 21:00 UTC | XPO, Inc. XPO · Entity 3242 | Exercise / conversionRestricted Stock Unit · Derivative | 2,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001166003-19-000037 · wf-form4_156028681955939.xml · derivative · entry 3 Glickman Sarah JS · CIK 0001749338 · Acting Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,208 Underlying: Common Stock, par value $0.001 per share · 2,842 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive, upon settlement, either (i) one share of Common Stock or (ii) a cash payment equal to the fair market value of one share of Common Stock. F3 · derivative.exercise_date: The RSUs vest in six equal annual installments, beginning on June 8, 2019 and continuing to vest on the next five anniversaries thereof, generally subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. F3 · derivative.expiration_date: The RSUs vest in six equal annual installments, beginning on June 8, 2019 and continuing to vest on the next five anniversaries thereof, generally subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 21:00 UTC | XPO, Inc. XPO · Entity 3242 | Tax withholdingCommon Stock, par value $0.001 per share | 891 | $53.78 | $47,917.98 |
DisclosureSEC source: 0001166003-19-000037 · wf-form4_156028681955939.xml · nonDerivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Acting Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,951 F1 · kind: No shares were sold by the Reporting Person. These shares were withheld by the Issuer to fund tax liability attributable to the vesting and settlement of the Restricted Stock Units ("RSUs") reported on this Form 4. These RSUs vested on June 8, 2019, as originally scheduled, and were settled on June 10, 2019, and there were no related discretionary transactions or open market sales. F1 · acquired: No shares were sold by the Reporting Person. These shares were withheld by the Issuer to fund tax liability attributable to the vesting and settlement of the Restricted Stock Units ("RSUs") reported on this Form 4. These RSUs vested on June 8, 2019, as originally scheduled, and were settled on June 10, 2019, and there were no related discretionary transactions or open market sales. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 21:00 UTC | XPO, Inc. XPO · Entity 3242 | Exercise / conversionCommon Stock, par value $0.001 per share | 2,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001166003-19-000037 · wf-form4_156028681955939.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Acting Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 20:41 UTC | XPO, Inc. XPO · Entity 3242 | GrantRestricted Stock Unit · Derivative | 1,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001166003-19-000027 · wf-form4_155596567970145.xml · derivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Acting Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 Underlying: Common Stock, par value $0.001 per share · 1,900 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive, upon settlement, either (i) one share of Common Stock or (ii) a cash payment equal to the fair market value of one share of Common Stock. F2 · derivative.exercise_date: The RSUs vest in two equal annual installments on the second and third anniversaries of the grant date, generally subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. F2 · derivative.expiration_date: The RSUs vest in two equal annual installments on the second and third anniversaries of the grant date, generally subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.